Publicaciones en colaboración con investigadores/as de Hospital de la Santa Creu i Sant Pau (17)

2024

  1. Predictive capacity for local disease control of neogenin-1 (NEO1) transcriptional expression in patients with head and neck squamous cell carcinoma

    Clinical and Translational Oncology

2022

  1. Semaphorin-3F/Neuropilin-2 Transcriptional Expression as a Predictive Biomarker of Occult Lymph Node Metastases in HNSCC

    Cancers, Vol. 14, Núm. 9

2021

  1. Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 1, pp. 45-58

  2. Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 8, pp. 2337-2353

  3. Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 1, pp. 59-70

2020

  1. Deletion or Inhibition of NOD1 Favors Plaque Stability and Attenuates Atherothrombosis in Advanced Atherogenesis †

    Cells, Vol. 9, Núm. 9

  2. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 5, pp. 1043-1057

  3. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 5, pp. 1023-1042

  4. Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines—Recommendations on the use of biologicals in severe asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 5, pp. 1058-1068

  5. Prognosis Assessment of Early-Stage Chronic Lymphocytic Leukemia: Are We Ready to Predict Clinical Evolution Without a Crystal Ball?

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 20, Núm. 8, pp. 548-555.e4

2019

  1. A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia

    Haematologica, Vol. 104, Núm. 2, pp. 288-296

  2. CIBER-CLAP (CIBERCV Cardioprotection Large Animal Platform): A multicenter preclinical network for testing reproducibility in cardiovascular interventions

    Scientific Reports, Vol. 9, Núm. 1

  3. Endothelial NOD1 directs myeloid cell recruitment in atherosclerosis through VCAM-1

    FASEB Journal, Vol. 33, Núm. 3, pp. 3912-3921

  4. Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR

    Scientific Reports, Vol. 9, Núm. 1

2017

  1. Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions

    Oncotarget, Vol. 8, Núm. 33, pp. 54297-54303

2016

  1. A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia

    Hematological Oncology, Vol. 34, Núm. 2, pp. 84-92

2013

  1. Analysis of the C9orf72 Gene in Patients with Amyotrophic Lateral Sclerosis in Spain and Different Populations Worldwide

    Human Mutation, Vol. 34, Núm. 1, pp. 79-82